These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32150672)

  • 1. Predicting the effect of 5-fluorouracil-based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles.
    Chen Q; Gao P; Song Y; Huang X; Xiao Q; Chen X; Lv X; Wang Z
    Cancer Med; 2020 May; 9(9):3043-3056. PubMed ID: 32150672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
    Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
    FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
    Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer.
    Tajima Y; Shimada Y; Kameyama H; Yagi R; Okamura T; Kobayashi T; Kosugi SI; Wakai T
    Jpn J Clin Oncol; 2017 Apr; 47(4):313-320. PubMed ID: 28100684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer.
    Kwon HY; Kim IK; Kang J; Sohn SK; Lee KY
    Cancer Res Treat; 2016 Jul; 48(3):970-7. PubMed ID: 26511802
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Lapucci A; Perrone G; Di Paolo A; Napoli C; Landini I; Roviello G; Calosi L; Naccarato AG; Falcone A; Bani D; Mini E; Nobili S
    Oncol Res; 2021 Mar; 28(6):631-644. PubMed ID: 33208224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Hitre E; Budai B; Adleff V; Czeglédi F; Horváth Z; Gyergyay F; Lövey J; Kovács T; Orosz Z; Láng I; Kásler M; Kralovánszky J
    Pharmacogenet Genomics; 2005 Oct; 15(10):723-30. PubMed ID: 16141798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
    Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
    Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.
    Huang Y; Yu H; Lei H; Xie C; Zhong Y
    Med Oncol; 2014 Mar; 31(3):824. PubMed ID: 24469951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
    Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
    Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients.
    Pardini B; Rosa F; Naccarati A; Vymetalkova V; Ye Y; Wu X; di Gaetano C; Buchler T; Novotny J; Matullo G; Vodicka P
    Carcinogenesis; 2015 Jan; 36(1):82-6. PubMed ID: 25368035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
    Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
    Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
    Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
    BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis.
    Yamadera M; Shinto E; Kajiwara Y; Mochizuki S; Okamoto K; Hase K; Yamamoto J; Ueno H
    Dis Colon Rectum; 2019 Nov; 62(11):1316-1325. PubMed ID: 31567925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRT17 as a prognostic biomarker for stage II colorectal cancer.
    Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
    Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.